Ceritinib
- Generic Name
- Ceritinib
- Brand Names
- Zykadia
- Drug Type
- Small Molecule
- Chemical Formula
- C28H36ClN5O3S
- CAS Number
- 1032900-25-6
- Unique Ingredient Identifier
- K418KG2GET
- Background
Ceritinib is used for the treatment of adults with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) following failure (secondary to resistance or intolerance) of prior crizotinib therapy. About 4% of patients with NSCLC have a chromosomal rearrangement that generates a fusion gene between EML4 (echinoderm microtubule-as...
- Indication
Ceritinib is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response. An improvement in survival or...
- Associated Conditions
- Refractory, locally advanced Non small cell lung cancer, Refractory, metastatic Non small cell lung cancer
- Associated Therapies
- -
A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.
- Conditions
- Interventions
- First Posted Date
- 2023-04-28
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 20605
- Registration Number
- NCT05834348
- Locations
- 🇳🇴
Pfizer Norway, Oslo, Norway
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
- First Posted Date
- 2022-08-05
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Giselle Sholler
- Target Recruit Count
- 76
- Registration Number
- NCT05489887
- Locations
- 🇺🇸
University of Alabama, Children's Alabama, Birmingham, Alabama, United States
🇺🇸Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸UCSF Benioff Children's Hospital Oakland-, Oakland, California, United States
Managed Access Programs for LDK378, Ceritinib
- First Posted Date
- 2021-10-29
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT05100134
Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.
- Conditions
- Interventions
- First Posted Date
- 2020-11-30
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 549
- Registration Number
- NCT04647110
- Locations
- 🇸🇪
Pfizer Innovations AB, Sollentuna, Sweden
Molecular Profiling of Advanced Soft-tissue Sarcomas
- Conditions
- Interventions
- First Posted Date
- 2018-12-21
- Last Posted Date
- 2024-04-10
- Target Recruit Count
- 603
- Registration Number
- NCT03784014
- Locations
- 🇫🇷
Centre Oscar Lambret, Lille, France
🇫🇷IUCT Oncopôle, Toulouse, France
🇫🇷Institut de Cancérologie de Montpellier, Montpellier, France
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-11-13
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 10
- Registration Number
- NCT03737994
- Locations
- 🇺🇸
Miller-Dwan Hospital, Duluth, Minnesota, United States
🇺🇸Fairview Southdale Hospital, Edina, Minnesota, United States
🇺🇸Grady Memorial Hospital, Delaware, Ohio, United States
Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC
- First Posted Date
- 2018-08-02
- Last Posted Date
- 2024-05-08
- Target Recruit Count
- 21
- Registration Number
- NCT03611738
- Locations
- 🇺🇸
Advent Health Orlando, Orlando, Florida, United States
🇺🇸H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors
- First Posted Date
- 2018-06-06
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Takeda
- Target Recruit Count
- 111
- Registration Number
- NCT03546894
- Locations
- 🇺🇸
EmpiraMed, Inc., Maynard, Massachusetts, United States
Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma
- Conditions
- Interventions
- First Posted Date
- 2018-04-18
- Last Posted Date
- 2024-12-04
- Target Recruit Count
- 27
- Registration Number
- NCT03501368
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2017-03-22
- Last Posted Date
- 2022-12-27
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 9
- Registration Number
- NCT03087448
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸University of California, Davis, Davis, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.